Navigation Links
Sangamo BioSciences Announces Presentation at the 10th Annual Needham Healthcare Conference
Date:3/29/2011

RICHMOND, Calif., March 29, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 3.20 pm ET on Tuesday, April 5, 2011 at the 10th Annual Needham Healthcare Conference which will be held in New York City.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and modification.  The most advanced ZFP Therapeutic® development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy. Sangamo also has a Phase 1/2 clinical trial and two ongoing Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS as well as a Phase 1 trial of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on Parkinson's disease, monogenic diseases, neuropathic pain and nerve regeneration.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins called zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.  Sangamo is also developing sequence-specific ZFP Nucleases
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results
2. Sangamo BioSciences Announces Fourth Quarter and Full Year 2010 Conference Call and Webcast
3. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
4. Sangamo BioSciences Announces Data Presentation of First In Vivo Demonstration of ZFN-mediated Gene Correction Via Systemic Delivery at American Society for Hematology Meeting
5. Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs
6. Sangamo BioSciences Announces Third Quarter 2010 Conference Call and Webcast
7. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
8. Sangamo BioSciences Announces Second Quarter 2010 Conference Call and Webcast
9. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
10. Sangamo BioSciences and Collaborators Present Data in Fifteen Presentations Highlighting Broad Therapeutic Applications of ZFP Technology
11. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 2014 First antibacterial ... a truly novel class of anti-infective in ... a biopharmaceutical company developing a truly novel ... has secured £4.0m ($6.4m) to advance the ... a range of Gram-positive infections including  Clostridium ...
(Date:9/16/2014)... 2014 This report analyzes the worldwide markets for ... Hardware, and Biocontent. The report provides separate comprehensive analytics for ... , Europe , Asia-Pacific ... of World. Annual estimates and forecasts are provided for the ... provided for these markets. Market data and analytics are derived ...
(Date:9/16/2014)... film for radar domes have now refined the technology ... , The new work by Rice chemist James Tour ... to skyscrapers free of ice and fog while retaining ... technology was introduced this month in the American Chemical ... , The material is made of graphene nanoribbons, atom-thick ...
(Date:9/16/2014)... DURHAM, N.C. , Sept. 16, 2014 /PRNewswire-USNewswire/ ... and oldest entrepreneurial support organization in the country, ... Innovators Report . It ... North Carolina startups in ... sectors drew more global investment from a variety ...
Breaking Biology Technology:MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Global Bioinformatics Industry 2Global Bioinformatics Industry 3Global Bioinformatics Industry 4Global Bioinformatics Industry 5Global Bioinformatics Industry 6Global Bioinformatics Industry 7Global Bioinformatics Industry 8Global Bioinformatics Industry 9Global Bioinformatics Industry 10Global Bioinformatics Industry 11Global Bioinformatics Industry 12Global Bioinformatics Industry 13Global Bioinformatics Industry 14Global Bioinformatics Industry 15Global Bioinformatics Industry 16Global Bioinformatics Industry 17Global Bioinformatics Industry 18Global Bioinformatics Industry 19Global Bioinformatics Industry 20Global Bioinformatics Industry 21Global Bioinformatics Industry 22Global Bioinformatics Industry 23Nanoribbon film keeps glass ice-free 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 3CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 4
... 2008 - Vol. 299. No. 8: ,Venous Thromboembolism and ... Administration for the Treatment of Cancer-Associated ... believes that,the conclusions of a study published in the ... Medical Association (JAMA) by Bennett, et al, do,not provide ...
... 26 CV Therapeutics,Inc. (Nasdaq: CVTX ) today reported ... 31, 2007., For the quarter ended December 31, 2007, ... per share. This compares to a net loss of,$68.1 million, ... and $34.2,million, or $0.58 per share, for the prior quarter ...
... REINACH, Switzerland, February 26 Arpida Ltd.,(SWX: ARPN) today ... (NDA) for intravenous iclaprim in its first indication,complicated Skin ... next few weeks., Arpida has agreed with the ... in a rolling process. Using a ,rolling NDA, allows ...
Cached Biology Technology:Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 2Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 3Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 4Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 5Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 6CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 2CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 3CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 4CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 5CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 6CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 7CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 8Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim 2Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim 3
(Date:9/16/2014)... rock hit the Yukatan peninsula near the site of the ... of TNT. It left a crater more than 150 km ... are widely accepted to have wiped out the dinosaurs and ... happened to the plants on which the dinosaurs fed? , ... Arizona reveals that the meteorite impact that spelled doom for ...
(Date:9/16/2014)... A complex web of interaction between viruses, bacteria, ... by a growing international collaboration between Matthew Sullivan, ... of Ecology and Evolutionary Biology and Steven Hallam ... Canada. , "Bacteria are drivers of nutrient ... said. "As the climate is changing, so are ...
(Date:9/16/2014)... Three years after the Hesperides vessel returned to Spain ... researchers have an increasingly clear picture of how the ... Specifically, the input of pollutants from the atmosphere is ... the most remote areas of the planet, and it ... findings are presented this week in CSIC Residence for ...
Breaking Biology News(10 mins):Meteorite that doomed the dinosaurs helped the forests bloom 2Meteorite that doomed the dinosaurs helped the forests bloom 3New research decodes virus-host interactions in ocean dead zones 2New research decodes virus-host interactions in ocean dead zones 3The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 2The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 3
... , May 30, 2013  Chiltern International Limited (Chiltern), a global ... Barbee to the position of Vice President, Global Biometrics. ... Chiltern stated: "We are extremely pleased to announce the promotion of ... to VP of Global Biometrics. In this role, Alecia will have ...
... for final exams might want to wait before pulling ... as their neurons are concerned. Carnegie Mellon University neuroscientists ... during which repeated exposure to a stimulus shrinks synapses. ... of the Journal of Neuroscience . It,s ...
... summit in Lough Erne, Northern Ireland, the German National ... science academies of the G8 member states and five ... state and government of the eight leading industrialised nations ... immediate future: drug-resistant infectious agents and sustainable development. The ...
Cached Biology News:Chiltern Announces The Promotion Of Alecia Barbee To VP, Global Biometrics 2Carnegie Mellon neuroscientists discover new phase of synaptic development 2The German National Academy of Sciences Leopoldina makes recommendations for the G8 summit 2
... screening, low melting point agarose where separation ... recommended for separation of nucleic acids less ... products. Micro ABgarose is also suited to ... blotting techniques. At a 3% concentration, Micro ...
Rabbit polyclonal to P5 ( Abpromise for all tested applications). entrezGeneID: 10954 SwissProtID: Q14554...
... Abpromise for all tested applications). ... derived from within residues 1 - 100 of ... is proprietary) (Peptide available as ... ID: 5453 Swiss Protein ...
Goat polyclonal to Sarcosine Oxidase ( Abpromise for all tested applications). Antigen: Microbial Sarcosine Oxidase. Entrez Gene ID: 51268 Swiss Protein ID: Q6IAJ9...
Biology Products: